Mesuximide
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (RS)-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione | |
| Clinical data | |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a682028 |
| Pregnancy cat. | C(US) |
| Legal status | ℞-only (US) |
| Routes | Oral |
| Pharmacokinetic data | |
| Metabolism | Hepatic (demethylation and glucuronidation) |
| Half-life | 1.4–2.6 hours (mesuximide) 28–38 hours (active metabolite) |
| Excretion | Renal |
| Identifiers | |
| CAS number | 77-41-8  |
| ATC code | N03AD03 |
| PubChem | CID 6476 |
| DrugBank | DB05246 |
| ChemSpider | 6231 |
| UNII | 0G76K8X6C0 |
| KEGG | D00404 |
| ChEMBL | CHEMBL697 |
| Chemical data | |
| Formula | C12H13NO2 |
| Mol. mass | 203.237 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Mesuximide (or methsuximide) is an succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methsuximide is largely due to its pharmacologically active metabolite, N-desmethylmethsuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]
[edit] References
- ^ Pfizer AG (2005). "Petinutin (Mésuximide)" (in French). Official Pfizer AG Website. http://www.pfizer.ch/internet/fr/home/products/central_nervous_system/epilepsy/petinutin_mesuximid.html. Retrieved August 21, 2006.[dead link]
- ^ Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. http://www.pfizer.com/products/rx/rx_product_celontin.jsp. Retrieved June 10, 2008.
- ^ Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it. |
